Osteoarthritis is a chronic degenerative disorder that ultimately leads to a gradual deterioration of joint cartilage.
Its onset can be caused by a combination of genes, age, weight gain, injury and overuse as well as bone, joint or metabolic disorders. Studies have found that some people have a rare defect that reduces collagen production and increases levels of FAAH – the gene responsible for pain sensitivity. In some instances, excessive weight gain, particularly fatty tissues, has found to produce inflammatory chemicals (cytokines) that damages joints. Repeated damage to joints, tendons and ligaments in combination with any of the above factors speeds up cartilage breakdown.
How Our Products Can Treat Osteoarthritis
We use products derived from human baby umbilical cord tissues in all our therapy programs - Wharton's Jelly MSCs (wjMSCs). Our products are special because they can:
There are currently 11 clinical trials exploring the use of wjMSCs in the treatment of osteoarthritis. These have been registered but results and findings have yet to be posted [33,34,35,36,37,38,39,40,41,42,43].
A 2008 American study found that, 24 weeks post-treatment, patients with degenerative joint disease in the knees had statistically significant cartilage and meniscus growth on MRI, as well as increased range of motion and decreased modified visual analog scale (VAS) pain scores .
It wasn’t until seven years later, that researchers at Royan Institute for Stem Cell Biology and Technology, Iran, performed a clinical trial on 18 patients with different joint involvements (osteoarthritis in the knee, ankle or hip). Patients were followed with clinical examinations, MRI and laboratory tests at 2, 6, 12, and 30 months post-transplantation. All patients were evaluated using a visual analog scale (VAS), which is a validated, subjective measure for acute and chronic pain  as well as Western Ontario and McMaster Universities OA Index (WOMAC) scores, which assesses pain stiffness and physical function in persons with hip and / or knee osteoarthritis . All patients exhibited therapeutic benefits such as increased walking distance, decreased VAS pain scores and total WOMAC scores which were corroborated by MRI scans .
A 2016 Indian clinical trial treated 60 patients with osteoarthritis in the knees. They were evaluated using visual analog scale (VAS) for pain , intermittent and constant osteoarthritis pain (ICOAP) and Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index  at the beginning then 1, 3, 6 and 12 months later. MRIs of the knee were also taken at the beginning, 6 and 12 months later for cartilage evaluation. Patients who received injections of 25 million cells per knee showed a trend towards improvement as well as effective pain reduction .
Late in 2018, Chilean researchers injected either single or repeated doses of wjMSCs into the knees of 9 osteoarthritis patients. They were evaluated at intervals of 1, 4, 8, 12, 24, 36, and 52 weeks with visual analog scale (VAS) for pain , Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index , 36-Item Short Form Health Survey (SF-36) to measure quality of life , Patient Global Assessment which assess pain, depression and anxiety, inability to participate, advanced age and degenerative arthritis  as well as the OMERACT-OARSI Responder Index Criteria which tabulates pain scores, functionality and a patient's global assessment . At the end of the trial, only MSC‐treated patients showed significant improvements in pain and function with 86% reduction in pain and 89% reduction in disability and improvements lasting the entire duration of the evaluation period. The repeated dose MSC group exhibited a significant advantage in pain reduction. At 12 months follow‐up, the WOMAC and VAS scores reached significantly lower levels compared to the other two groups .
Achieving high standards in our work is of paramount importance to us. Depending on a patient’s needs, we combine our premium grade Passage 2 wjMSCs with physiotherapy, occupational therapy, speech and language therapy and/or rehabilitative medicine.
Why Choose Cyrona?
All our therapy packages come inclusive of:
How Do We Proceed
All our therapies are charged based on the number of wjMSCs and supplementary infusions required for the patient’s specific condition. As no two people are alike, our specialists review each patient’s medical reports before tailoring a therapy catered to addressing his or her individual needs.
You may chat with one of our Customer Care Representatives or send an e-mail detailing the patient’s condition to one of our Liaison Officers. It would expedite the process if you can provide us with:
Upon getting in touch with us, a Liaison Officer evaluates and assigns the case to the specialist best equipped to treat the condition. A therapy, unique only to the patient, is drawn up and a price quoted accordingly.
Should you decide to proceed with therapy, our specialists require that all patients have Cancer Marker Screening performed in their country of residence before travelling to us for therapy. If the patient has had Cancer Marker Screening within the last 3 months, you may e-mail those results to us. In the event that the patient’s Cancer Marker Screening results are not satisfactory, our specialists will refuse to proceed with therapy. It is for this reason that we requests that patients have Cancer Marker Screening performed in their country of residence prior to travelling to us.
One week prior to arrival, a deposit payment is required in order to arrange accommodation and transportation.
Full payment is required to be made one-day prior to therapy commencement.
Post-treatment, our specialist will provide the patient with a post-treatment protocol as well as what to expect on his or her journey towards a better, and hopefully, healthier new life.
Download our eBook and receive our weekly in-depth and exclusive newsletter about Osteoarthritis.